Your Article Summary
See Latest ArticlesComplete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment
Arthritis & Rheumatism, 06/04/09
Kim S et al. – Findings suggest that aggressive treatment of juvenile dermatomyositis (DM) aimed at achieving rapid, complete control of muscle weakness and inflammation improves outcomes and reduces disease-related complications, leading into prolonged, medication-free remission within a median of 38 months from the time of diagnosis.
Methods- An assessment of the time needed to achieve sustained, medication-free remission in pts with juvenile DM receiving a stepwise, aggressive treatment protocol
- 49 children with juvenile DM received standardized therapy with steroids and methotrexate
- If a pt's strength or muscle enzyme levels did not normalize with this initial therapy, additional medications were added in rapid succession to the treatment regimen
- Primary outcome measure: time to complete remission
- Additional outcome measures: onset of calcinosis, effect of treatment on height, and complications resulting from medications
- 49 pts were followed up for a mean of 48 mo
- All but 1 patient received ≥2 medications simultaneously
- Transient localized calcifications occurred in 8%, and 4% additional had persistent calcinosis
- Despite the aggressive therapy, complications associated with treatment were mild and were primarily attributable to steroids
- No persistent effect on longitudinal growth was observed
- A complete, medication-free remission was achieved in 28 pts
- Median time to achievement of CR was 38 mo
- None of these pts experienced a disease flare that required resumption of medications during the subsequent period of observation
Related Articles
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment
Best Practice & Research: Clinical Rheumatology, 10/28/09
Relevance Score: 67%
Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis
Scandinavian Journal of Rheumatology, 10/08/09
Relevance Score: 67%
Juvenile Dermatomyositis: Advances in Pathogenesis, Evaluation, and Treatment
Pediatric Drugs, 11/09/09
Relevance Score: 65%
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis
Arthritis & Rheumatism, 11/12/09
Relevance Score: 64%
Rheumatic manifestations of parvovirus B19 in children
Journal of Pediatric Infectious Diseases, 10/15/09
Relevance Score: 64%
Today in Pediatric Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Low cortisol levels in active juvenile idiopathic arthritis
Clinical Rheumatology, 12/20/09
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis
Rheumatology, 12/20/09
A case of juvenile idiopathic polyarticular arthritis complicated by IgA deficiency in 22q11 deletion syndrome
Rheumatology International, 12/19/09